Vasculogenic mimicry in small cell lung cancer

Research output: Contribution to journalArticle

  • External authors:
  • Stuart C Williamson
  • Robert L Metcalf
  • Francesca Trapani
  • Sumitra Mohan
  • Jenny Antonello
  • Hui Sun Leong
  • Christopher Chester
  • Nicole Simms
  • Radoslaw Polanski
  • Daisuke Nonaka
  • Lynsey Priest
  • Alberto Fusi
  • Fredrika Carlsson
  • Anders Carlsson
  • Mary J C Hendrix
  • Richard E B Seftor
  • Elisabeth A Seftor
  • Dominic G Rothwell
  • Andrew Hughes
  • James Hicks
  • Crispin Miller
  • Peter Kuhn
  • Gerard Brady
  • Kathryn L Simpson
  • Caroline Dive


Small cell lung cancer (SCLC) is characterized by prevalent circulating tumour cells (CTCs), early metastasis and poor prognosis. We show that SCLC patients (37/38) have rare CTC subpopulations co-expressing vascular endothelial-cadherin (VE-cadherin) and cytokeratins consistent with vasculogenic mimicry (VM), a process whereby tumour cells form 'endothelial-like' vessels. Single-cell genomic analysis reveals characteristic SCLC genomic changes in both VE-cadherin-positive and -negative CTCs. Higher levels of VM are associated with worse overall survival in 41 limited-stage patients' biopsies (P<0.025). VM vessels are also observed in 9/10 CTC patient-derived explants (CDX), where molecular analysis of fractionated VE-cadherin-positive cells uncovered copy-number alterations and mutated TP53, confirming human tumour origin. VE-cadherin is required for VM in NCI-H446 SCLC xenografts, where VM decreases tumour latency and, despite increased cisplatin intra-tumour delivery, decreases cisplatin efficacy. The functional significance of VM in SCLC suggests VM regulation may provide new targets for therapeutic intervention.

Bibliographical metadata

Original languageEnglish
Pages (from-to)13322
JournalNature Communications
Publication statusPublished - 9 Nov 2016